ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Cross Below Fifty Day Moving Average of $57.70

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $57.70 and traded as low as $56.26. ProShares Ultra Nasdaq Biotechnology shares last traded at $58.09, with a volume of 230,404 shares traded.

ProShares Ultra Nasdaq Biotechnology Stock Performance

The firm’s 50 day moving average price is $57.70 and its 200-day moving average price is $52.10.

ProShares Ultra Nasdaq Biotechnology Announces Dividend

The business also recently declared a dividend, which was paid on Wednesday, March 27th. Investors of record on Thursday, March 21st were given a dividend of $0.0403 per share. The ex-dividend date was Wednesday, March 20th.

Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology

A number of hedge funds have recently made changes to their positions in the company. Vontobel Holding Ltd. grew its stake in ProShares Ultra Nasdaq Biotechnology by 11.6% during the 1st quarter. Vontobel Holding Ltd. now owns 3,321 shares of the exchange traded fund’s stock valued at $206,000 after acquiring an additional 344 shares in the last quarter. JPMorgan Chase & Co. lifted its position in ProShares Ultra Nasdaq Biotechnology by 25.3% during the first quarter. JPMorgan Chase & Co. now owns 2,495 shares of the exchange traded fund’s stock worth $135,000 after buying an additional 504 shares in the last quarter. UBS Group AG boosted its stake in ProShares Ultra Nasdaq Biotechnology by 213.6% during the third quarter. UBS Group AG now owns 1,151 shares of the exchange traded fund’s stock worth $55,000 after buying an additional 784 shares during the last quarter. Toth Financial Advisory Corp grew its holdings in ProShares Ultra Nasdaq Biotechnology by 17.3% in the 4th quarter. Toth Financial Advisory Corp now owns 11,241 shares of the exchange traded fund’s stock valued at $641,000 after buying an additional 1,655 shares in the last quarter. Finally, Simplex Trading LLC grew its holdings in ProShares Ultra Nasdaq Biotechnology by 5,408.9% in the 4th quarter. Simplex Trading LLC now owns 2,479 shares of the exchange traded fund’s stock valued at $141,000 after buying an additional 2,434 shares in the last quarter.

About ProShares Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.